Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: A retrospective analysis in the Nagoya Blood and Marrow Transplantation Group

International Journal of Hematology

Volumn 87, Issue 2, 2008, Pages 210-216

  Kohno, Akio ^a   Morishita, Yoshihisa ^a   Iida, Hiroatsu ^b   Yanada, Masamitsu ^c   Uchida, Toshiki ^d   Hamaguchi, Motohiro ^e   Sawa, Masashi ^f   Sugiura, Isamu ^g   Yamamoto, Kazuhito ^h   Mizuta, Shuichi ⁱ   Sao, Hiroshi ^b   Naoe, Tomoki ^c   Miyamura, Koichi ^j  

^a JA Aichi Showa Hospital   (Japan)

^b Meitetsu Hospital   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^f ANJO KOSEI HOSPITAL   (Japan)

^g TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^h AICHI CANCER CENTER HOSPITAL   (Japan)

ⁱ FUJITA HEALTH UNIVERSITY HOSPITAL   (Japan)

^j JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

more..

Author keywords

Acute promyelocytic leukemia; Hematopoietic stem cell transplantation; Minimal residual disease

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; MELPHALAN; RETINOIC ACID; TAMIBAROTENE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CAUSE OF DEATH; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; INTERMETHOD COMPARISON; INTERSTITIAL PNEUMONIA; LEUKEMIA RELAPSE; LIVER TOXICITY; MALE; OVERALL SURVIVAL; PROMYELOCYTIC LEUKEMIA; QUALITY OF LIFE; REMISSION; SALVAGE THERAPY; SCORING SYSTEM; STOMATITIS; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 42049120289     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0020-8     Document Type: Article

References (14)

1. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002;99(3):759-67.
2. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002;100(13):4298-302.
3. Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol. 1998;16(1):78-85.
4. Thomas X, Dombret H, Cordonnier C, et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia. Leukemia. 2000;14(6):1006-13.
5. Thomas X, Anglaret B, Thiebaut A, et al. Improvement of prognosis in refractory and relapsed acute promyelocytic leukemia over recent years: the role of all-trans retinoic acid therapy. Ann Hematol. 1997;75(5-6):195-200.
6. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89(9):3354-60.
7. Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol. 2005;23(10):2396-410.
8. Tobita T, Takeshita A, Kitamura K, et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood. 1997;90(3):967-73.
9. Shinjo K, Takeshita A, Ohnishi K, et al. Good prognosis of patients with acute promyelocytic leukemia who achieved second complete remission (CR) with a new retinoid, Am80, after relapse from CR induced by all-trans-retinoic acid. Int J Hematol. 2000;72(4):470-3.
10. Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood. 1998;92(4):1073-90.
11. Meloni G, Diverio D, Vignetti M, et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood. 1997;90(3):1321-5.
12. de Botton S, Fawaz A, Chevret S, et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol. 2005;23(1):120-6.
13. Ferrara F, Palmieri S, Annunziata M, et al. Prolonged molecular remission after autologous stem cell transplantation in relapsed acute promyelocytic leukemia. Haematologica. 2004;89(5):621-2.
14. Grimwade D. The significance of minimal residual disease in patients with t(15;17). Best Pract Res Clin Haematol. 2002;15(1):137-58.